Have any questions? 706-721-6582 or cts@augusta.edu
- HZNP-HZN-1116-201: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
Clinical Trial
HZNP-HZN-1116-201: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
The purpose of this study is to evalue the effect of the study drug, HZN-1116, on signs and symptoms of Sjogren's Syndrome in participants with moderate-to-severe systemic disease activity.
Eligibility Criteria
- INCLUSION: 1. Adults age 18 or older with Sjogren's Syndrome, meeting specific sign/symptom evaluation criteria 2. Vaccinated against COVID-19, meets protocol criteria regarding tuberculosis EXCLUSION: 1. No presence or history of protocol-prohibited medical conditions 2. No current/previous use of medications as specified in the protocol 3. No lab test values outside of protocol-defined acceptable ranges
RESEARCH. INNOVATION. DISCOVERY.